The Growing GLP-1 Therapy Market

Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.  

Learnings from both Byetta and its own experience with Victoza helped Novo Nordisk develop and launch what it hopes will become a best in class therapy, with a strong life cycle management program and additional indications entering the clinic. The $12bn market for GLP-1 therapies has gotten crowded in recent years; Eli Lilly hopes its follow up to Trulicity (dulaglutide), the experimental combination product tirzepatide, a “dual glucose-dependent insulinotropic polypeptide (GIP) and GLP agonist," will help it maintain a leadership position. (Also see "Brand Spotlight: Novo Nordisk’s Semaglutide" - In Vivo, 15 April, 2021.) However, new indications in areas of massive unmet need, such as Alzheimer’s and obesity, could push Novo’s semaglutide over the top in the coming years. 

Dr. John Eng discovers a novel peptide hormone in the venom of a Gila monster

More from Innovation

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.